Skip to content
CancerIndex

Loading the knowledge graph…

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT — knowledge graph · CancerIndex